C1S.F China Shineway Pharmaceutical Group Limited
- Market cap
- EUR 657M
- P/E
- 6.7x
- P/B
- 0.59x
- ROE
- 11.8%
- Dividend yield
- 18.58%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is C1S.F undervalued?
Graham numberC1S.F trades 58.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Shineway Pharmaceutical Group Limited fundamental analysis
No fundamental analysis for China Shineway Pharmaceutical Group Limited yet.
China Shineway Pharmaceutical Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, …
Full company profileChina Shineway Pharmaceutical Group Limited financial statements
China Shineway Pharmaceutical Group Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.99B | 1.92B | 2.57B | 2.71B | 2.66B | 3.22B | 3.95B | 4.52B | 3.78B | 3.14B |
| Gross Profit | 1.29B | 1.27B | 1.88B | 1.98B | 1.99B | 2.41B | 2.94B | 3.39B | 2.83B | 2.27B |
| Operating Income | 584M | 483M | 494M | 476M | 429M | 541M | 722M | 976M | 843M | 718M |
| EBITDA | - | 682M | 696M | 850M | 412M | 721M | 1.10B | 1.30B | 1.22B | 1.35B |
| Net Income | 589M | 452M | 506M | 503M | 295M | 557M | 723M | 970M | 840M | 950M |
| EPS | - | 0.55 | 0.61 | 0.61 | 0.36 | 0.67 | 0.87 | 1.17 | 1.11 | 1.26 |
| Balance Sheet | ||||||||||
| Total Assets | 6.47B | 6.67B | 6.73B | 7.13B | 7.21B | 7.20B | 8.23B | 9.57B | 10.0B | 10.8B |
| Total Liabilities | 839M | 844M | 966M | 1.35B | 1.42B | 1.30B | 1.85B | 2.54B | 2.57B | 2.72B |
| Shareholders' Equity | 5.63B | 5.82B | 5.77B | 5.78B | 5.79B | 5.90B | 6.38B | 7.03B | 7.47B | 8.06B |
| Cash & Short-term Investments | 3.22B | 3.53B | 3.61B | 3.95B | 3.94B | 4.21B | 5.03B | 5.89B | 6.14B | 7.19B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 734M | 491M | 533M | 368M | 639M | 703M | 1.11B | 933M | 963M | 1.17B |
| Capital Expenditure | 107M | 91.8M | 127M | 88.4M | 66.0M | 93.6M | 129M | 144M | 140M | 198M |
| Free Cash Flow | - | 399M | 393M | 277M | 573M | 610M | 980M | 788M | 823M | 974M |
| Ratios | ||||||||||
| ROE | 10.5% | 7.8% | 8.8% | 8.7% | 5.1% | 9.4% | 11.3% | 13.8% | 11.3% | 11.8% |
| ROA | 9.1% | 6.8% | 7.5% | 7.1% | 4.1% | 7.7% | 8.8% | 10.1% | 8.4% | 8.8% |
| Net Profit Margin | 29.6% | 23.5% | 19.7% | 18.6% | 11.1% | 17.3% | 18.3% | 21.5% | 22.2% | 30.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
China Shineway Pharmaceutical Group Limited dividends
- Dividend yield
- 18.58%
- Forward dividend
- 0.16 EUR
- Payout ratio
- 37.4%
- Ex-dividend date
- Oct 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 355M | 0.47 | 37.4% |
| 2024 | CNY 408M | 0.54 | 48.6% |
| 2023 | CNY 317M | 0.38 | 32.7% |
| 2022 | CNY 242M | 0.29 | 33.4% |
| 2021 | CNY 453M | 0.55 | 81.4% |
| 2020 | CNY 174M | 0.21 | 58.8% |
| 2019 | EUR 179M | 0.22 | 35.5% |
| 2018 | EUR 188M | 0.23 | 37.1% |
| 2017 | EUR 190M | 0.23 | 42.1% |
| 2016 | EUR 265M | - | 44.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns China Shineway Pharmaceutical Group Limited
- Insiders 66.31%
- Institutions 5.03%
- Public & others 28.67%
- Shares outstanding 755M
- Free float 207M
China Shineway Pharmaceutical Group Limited company profile
- Company name
- China Shineway Pharmaceutical Group Limited
- Ticker
- C1S.F
- ISIN
- KYG2110P1000
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,656
- Fiscal year end
- December
- Address
- Luan Cheng District, Shijiazhuang, China, 051430
- Phone
- 86 31 1880 30066
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of Forway Investment Limited.
China Shineway Pharmaceutical Group Limited management
4- Mr. Zhenjiang LiCo-Founder & Executive Chairman · born 1955
- Mr. Huimin LiExecutive Director · born 1968
- Mr. Bun Ching LeeFinancial Controller & Company Secretary · born 1973
- Mr. King Kuen Hung AICPA, HKICPA, MBADirector of Investor Relation · born 1966